Ron Wyden sold Pfizer Inc (NYSE: PFE)
Ron Wyden (D-OR), a U.S. Senator, has disclosed 1 trade in Pfizer Inc (PFE) since 2025, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Ron Wyden sold $1,001 - $15,000 of Pfizer Inc (NYSE: PFE) on June 3, 2025. Since that trade, PFE is up +11.11% against the S&P 500 up +27.57%, an outperformance of -16.46%.
Data updated
Ron Wyden's PFE trades vs the price
PFE is up +11.11% since Ron Wyden sold on June 3, 2025, versus +27.57% for the S&P 500.
Performance since this trade
All Ron Wyden PFE trades
Ron Wyden & PFE trading FAQ
Is it legal for Ron Wyden to trade Pfizer Inc (PFE) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Pfizer Inc (PFE), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Ron Wyden sell PFE?
Ron Wyden disclosed a sale of $1,001 - $15,000 of Pfizer Inc (PFE) on June 3, 2025, according to public STOCK Act filings.
How has PFE performed since Ron Wyden's trade?
Since Ron Wyden sold PFE on June 3, 2025, the stock is up +11.11%, versus +27.57% for the S&P 500 over the same period, an outperformance of -16.46%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional PFE trades?
Quantellect tracks every disclosed congressional trade in Pfizer Inc (PFE) on the Pfizer Inc congressional trading page, which aggregates filings across all members of Congress.
Ron Wyden's PFE tradesAll congressional filings for Pfizer IncRon Wyden's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.